Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Treasury Shares (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Treasury Shares for 8 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Treasury Shares changed 0.0% year-over-year to $8.9 million, compared with a TTM value of $8.9 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $8.9 million, changed 0.0% over the prior year.
  • Treasury Shares was $14792.0 for Q4 2025 at Abvc Biopharma, up from -$730641.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $14792.0 in Q4 2025 and bottomed at -$730641.0 in Q3 2025.
  • Average Treasury Shares over 4 years is -$422869.1, with a median of -$730049.0 recorded in 2024.
  • The sharpest move saw Treasury Shares decreased 2.18% in 2023, then grew 0.09% in 2024.
  • Year by year, Treasury Shares stood at $9.1 million in 2021, then changed by 0.0% to $9.1 million in 2022, then decreased by 2.18% to $8.9 million in 2023, then rose by 0.09% to $8.9 million in 2024, then changed by 0.0% to $8.9 million in 2025.
  • Business Quant data shows Treasury Shares for ABVC at $8.9 million in Q4 2025, $8.9 million in Q3 2025, and $8.9 million in Q2 2025.